VHL抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P00779(VHL Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P00779(VHL Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

**Background of VHL Antibodies**

VHL (von Hippel-Lindau) antibodies are essential tools for studying the VHL protein, encoded by the *VHL* tumor suppressor gene located on chromosome 3p25.3. The VHL protein (pVHL) is a critical component of the E3 ubiquitin ligase complex, which targets hypoxia-inducible factors (HIF-1α and HIF-2α) for proteasomal degradation under normoxic conditions. This regulation prevents aberrant activation of hypoxia-responsive genes involved in angiogenesis, cell proliferation, and metabolism.

Mutations or deletions in the *VHL* gene disrupt this process, leading to HIF accumulation and promoting tumorigenesis. VHL dysfunction is hallmark of von Hippel-Lindau disease, a hereditary cancer syndrome predisposing individuals to benign and malignant tumors, including renal cell carcinoma, pheochromocytoma, and hemangioblastomas.

VHL antibodies are widely used in research to detect VHL expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They aid in studying VHL's role in oxygen sensing, tumor suppression, and its interaction with partner proteins (e.g., elongin B/C, cullin-2). Some antibodies specifically recognize wild-type or mutant VHL isoforms, facilitating mechanistic studies in cancer models or clinical diagnostics.

Clinically, VHL antibodies may help assess VHL status in tumors, guiding therapeutic strategies targeting HIF pathways. Their utility extends to exploring VHL's emerging roles in extracellular matrix regulation and cilia function. Ensuring antibody specificity remains crucial due to post-translational modifications and isoform diversity of VHL.